Climb Bio (CLYM) Change in Accured Expenses (2020 - 2026)

Climb Bio has reported Change in Accured Expenses for 7 years, with the latest figure at -$1.5 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 175.28% year-over-year to -$1.5 million; the trailing twelve-month figure through Mar 2026 stood at -$3.6 million (down 184.43% YoY), and the FY2024 full-year result was $1.4 million, changed N/A from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$1.5 million, down from -$152000.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $2.8 million in Q3 2023, with the low at -$1.7 million in Q3 2022.
• Historically, Change in Accured Expenses has averaged $21125.0 across 5 years, with a median of -$28500.0 in 2024.
• The largest YoY upside for Change in Accured Expenses was 373.15% in 2025 against a maximum downside of 933.68% in 2025.
• Climb Bio's Change in Accured Expenses stood at $613000.0 in 2022, then surged by 355.46% to $2.8 million in 2023, then slumped by 63.32% to $1.0 million in 2024, then plunged by 114.84% to -$152000.0 in 2025, then plunged by 907.89% to -$1.5 million in 2026.
• The last three Change in Accured Expenses figures came in at -$1.5 million (Q1 2026), -$152000.0 (Q4 2025), and -$792000.0 (Q3 2025), per Business Quant data.